Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of REMEMBER-fX (HT1001, an extract of Panax quinquefolius) in a human sample using standard clinical neuropsychological instruments and side effects rating scales.


Clinical Trial Description

Panax ginseng has been used in Asia for thousands of years to improve vitality, wakefulness, respiration, angina, nausea, attention, memory, and diminished libido. More recently, Panax extracts have become one of the most popular commercial herbal dietary supplements in the West as well. Unfortunately, a limited understanding of the bioactive ingredients within the Panax extracts resulted in a wide spectrum of available products with no guidelines for standardization. The lack of standardization undermined any legitimate attempt to validate the claimed health benefits of the extracts. However, recent advances in the identification, quantification, and standardization of extract components with demonstrated systemic and neurological actions in animals have created a novel opportunity for the controlled clinical investigation of some Panax extracts.

A significant improvement in the standardization of Panax extracts occurred approximately 20 years ago with the introduction of a 4% minimum ginsenoside content in a formulation of Panax ginseng C V Meyer under the trademark G115 by Pharmaton in Lugano Switzerland. This prompted a series of investigations of short-term cognitive, physical, emotional, and psychosocial benefits from a single dose of G115. Idiosyncratic cognitive gains were reported, but no reliable benefits were observed in physical, emotional, or psychosocial status. Several studies have examined the cognitive, physical, emotional, and psychosocial benefits from sustained exposure to G115, but these studies are few in number and often failed to include standardized behavioural measures or controlled Panax extracts.

Over the past five years, refinements in high pressure liquid chromatography (HPLC) have allowed greater precision in Panax constituent analysis, with significant implications to the investigation of the safety and efficacy of Panax extracts in human populations. HPLC has been used to identify and quantify several promising neuroactive ginsenosides that are likely relevant to the human bioactive effect of Panax extracts. Most notable are the Rg1 and Rb1 ginsenosides from Panax quinquefolius L which show a number of interesting in vitro effects on animal tissue from the central nervous system that have led to several positive results from studies of animal learning. Most significant, however, was the introduction of HT1001, a precisely standardized proprietary combination of Rg1 and Rb1 ginsenosides developed by CV Technologies in Edmonton, Alberta, Canada. Each product lot of HT1001 from CV Technologies is tested to ensure consistency of the ginsenoside composition. The introduction of a commercial product with a precise standardized composition of Rb1 and Rg1 has created a unique opportunity for investigating the safety and efficacy of Panax extracts. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00527969
Study type Interventional
Source Afexa Life Sciences Inc
Contact
Status Completed
Phase Phase 2
Start date July 2007

See also
  Status Clinical Trial Phase
Withdrawn NCT04540523 - Home-Based Exergaming Intervention N/A
Suspended NCT01212029 - Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging N/A
Enrolling by invitation NCT05273970 - Electrochemical and Electrophysiological Study N/A
Recruiting NCT05227352 - Bio-Experiential Spaces for Mental Health in Healthworkers N/A
Completed NCT02671149 - The Effect of Small Changes in Hydration on Cognition N/A
Completed NCT01333306 - Enhancing Cognitive Training Using tDCS Phase 1
Recruiting NCT05542199 - Nutrition for Brain and Body Health (BB-Health) Feasibility Trial N/A
Recruiting NCT06331286 - The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity N/A
Recruiting NCT06254638 - Effectiveness of a Multicomponent Intervention to Promote Physical Activity Levels During the School Day (MOVESCHOOL) N/A
Completed NCT05998096 - A Randomized Study to Examine the Ability of a Caffeine-Based Energy Drink to Impact Energy Expenditure, Fat Oxidation, Reaction Time, and Other Perceptual Indicators N/A
Withdrawn NCT03224559 - Applying Neuromodulation to Accelerate Training Effects
Completed NCT03129048 - Mediterranean Diet, Weight Loss, and Cognition in Obese Older Adults N/A
Recruiting NCT05394363 - Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
Suspended NCT05107947 - Light in Frail Elderly - the Effect of a Dynamic Light for Sleep and Circadian Rhythm N/A
Recruiting NCT05372172 - Tennessee Alzheimer's Project
Recruiting NCT05132517 - Magnesium and Cognition After Stroke
Recruiting NCT05992571 - Oral Ketone Monoester Supplementation and Resting-state Brain Connectivity N/A
Recruiting NCT06097182 - Postbiotic Intervention for Acute Stress Management N/A
Completed NCT01223404 - Nicotinic Modulation of the Default Network N/A
Completed NCT00687102 - Cognition in the Study of Tamoxifen and Raloxifene Phase 3